CAS:63223-86-9
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Array ( [133] => Array ( [id] => 133 [name] => Inhibitors & Antagonists & Agonists [children] => Array ( [352] => Array ( [id] => 352 [name] => Protein Tyrosine Kinase/PTK ) [350] => Array ( [id] => 350 [name] => PI3K/Akt/mTOR ) [351] => Array ( [id] => 351 [name] => Endocrinology & Hormones ) [357] => Array ( [id] => 357 [name] => Angiogenesis ) [358] => Array ( [id] => 358 [name] => HIF ) [363] => Array ( [id] => 363 [name] => Immunology & Inflammation ) [364] => Array ( [id] => 364 [name] => Stem Cells ) [365] => Array ( [id] => 365 [name] => Apoptosis ) [377] => Array ( [id] => 377 [name] => Metabolic Enzyme & Protease ) [379] => Array ( [id] => 379 [name] => Autophagy ) [380] => Array ( [id] => 380 [name] => ER Stress ) [384] => Array ( [id] => 384 [name] => Cell Cycle ) [385] => Array ( [id] => 385 [name] => Cytoskeleton ) [386] => Array ( [id] => 386 [name] => DNA Damage & DNA Repai ) [387] => Array ( [id] => 387 [name] => Epigenetics ) [388] => Array ( [id] => 388 [name] => Ubiquitin ) [389] => Array ( [id] => 389 [name] => JAK/STAT ) [390] => Array ( [id] => 390 [name] => GPCR & G Protein ) [391] => Array ( [id] => 391 [name] => Neuronal Signal Pathway ) [392] => Array ( [id] => 392 [name] => MAPK ) [393] => Array ( [id] => 393 [name] => NF-κB ) [394] => Array ( [id] => 394 [name] => Membrane Transporter & Ion Channel ) [395] => Array ( [id] => 395 [name] => TGF-β/Smad ) [396] => Array ( [id] => 396 [name] => Hippo ) [775] => Array ( [id] => 775 [name] => Antibody-drug Conjugate/ADC Related ) [122] => Array ( [id] => 122 [name] => Others ) ) [num] => Array ( [0] => Array ( [count(*)] => 2140 ) ) ) )
>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Cell Cycle >
Ginsenoside Rh1CAS:63223-86-9
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
CAS | 63223-86-9 |
Chinese Name | 人参皂苷Rh1 |
English Name | Ginsenoside Rh1 |
Synonyms | Sanchinoside B2;Sanchinoside Rh1;Prosapogenin A2;20(S)-Ginsenoside Rh1 |
Molecular Formula | C36H62O9 |
Molecular Weight | 638.88 |
Solubility | Soluble in DMSO ≥100mg/mL |
Purity | HPLC≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD09951797 |
SMILES | C[C@@]([C@@]12C)(C[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]3O)O)([H])O[C@@H]3CO)[C@@]4([H])C5(C)C)[C@@](C[C@@H](O)[C@]1([H])[C@]([C@@](C)(O)CC/C=C(C)/C)([H])CC2)([H])[C@]4(CC[C@@H]5O)C |
InChIKey | RAQNTCRNSXYLAH-RFCGZQMISA-N |
InChI | InChI=1S/C36H62O9/c1-19(2)10-9-13-36(8,43)20-11-15-34(6)26(20)21(38)16-24-33(5)14-12-25(39)32(3,4)30(33)22(17-35(24,34)7)44-31-29(42)28(41)27(40)23(18-37)45-31/h10,20-31,37-43H,9,11-18H2,1-8H3/t20-,21+,22-,23+,24+,25-,26-,27+,28-,29+,30-,31+,33+,34+,35+,36-/m0/s1 |
PubChem CID | 12855920 |
Target Point | TNF-α;PPAR;IL-6,IL-1β |
Passage | Apoptosis;Cell Cycle;DNA Damage/DNA Repair;Metabolic Enzyme&Protease;Immunology & Inflammation |
Background | Ginsenoside Rh1 inhibits the expression of PPAR-γ, TNF-α, IL-6 and IL-1β. |
Biological Activity | Ginsenoside Rh1 是从 Panax Ginseng 根部分离的。 Ginsenoside Rh1 抑制 PPAR-γ,TNF-α,IL-6 和 IL-1β 的表达。[1] |
In Vitro | 检测人参皂甙Rh1对3T3-L1细胞中脂肪形成的影响。如通过油红O染色和3T3-L1脂肪细胞中的脂质含量所评估,人参皂苷Rh1有效抑制脂肪形成。浓度为50μM和100μM的人参皂苷Rh1分别抑制脂肪形成50%和63%。检测脂肪细胞特异性基因如PPAR-γ,C/EBP-α,FAS,aFABP和一些基因的表达水平。在分化的早期阶段,例如Pref-1,C/EBP-δ和糖皮质激素受体(GR)。在3T3-L1细胞中用人参皂甙Rh1处理后,对于Pref-1,C/EBP-δ和GR以及第8天,对于PPAR-γ,C/EBP-α,FAS,aFABP,在18小时和24小时提取mRNA。 。然后,通过RT-PCR研究脂肪细胞特异性基因的表达谱。与未刺激的脂肪细胞相比,DMI刺激的分化脂肪细胞中PPAR-γ,C/EBP-α,FAS和aFABP表达显著增加。然而,在人参皂苷Rh1存在下用DMI处理以剂量依赖性方式显著抑制PPAR-γ,C/EBP-α,FAS和aFABP的表达水平,而Pref-1,C/EBP的表达水平-δ和GR不受影响[1]。 |
In Vivo | 当高脂肪饮食(HFD)喂养小鼠8周时,与低脂肪饮食(LFD)喂养的小鼠相比,身体和附睾脂肪重量增加显著增加。然而,当在喂食HFD的小鼠中处理人参皂苷Rh1时,与喂食HFD的小鼠相比,身体和附睾脂肪重量增加显著降低。与LFD喂养的小鼠组相比,HFD喂养的小鼠组中血液中的TG,葡萄糖,胰岛素,总胆固醇和HDL水平显著增加。在HFD喂养的小鼠中用人参皂苷Rh1处理显著降低单独的TG水平[1]。 |
Cell Experiment | 将小鼠胚胎成纤维细胞3T3-L1细胞在含有10%FBS和1%AB的DMEM中于37℃和5.6%CO 2气氛中温育。为了诱导分化,在汇合后两天,在分化培养基(DM)中培养前脂肪细胞(指定为第0天),其由DMEM,10%FBS,1%AB和DMI(0.28单位/ mL胰岛素,0.5mM)组成。在存在或不存在50μM和100μM人参皂苷Rh1的情况下,异丁基甲基黄嘌呤和1μM地塞米松2天,并转换为含有10%FBS和10μg/ mL胰岛素的DM,然后换成含有10%FBS的DMEM培养基2 d [1]。 |
Animal Experiment | 小鼠[1]将雄性C57BL/6J小鼠分成3组,LFD,HFD和HFDRh1。每组由10只小鼠组成。 LFD组喂食LFD 8周。 HFD组喂养HFD 8周。 HFDRh1组喂食HFD饮食4周,然后同时用HFD和20mg/kg/d人参皂苷Rh1进行口服给药。每天测量小鼠的体重和食物摄入量。在完成治疗4周后,收集血液和附睾脂肪用于进一步分析。 |
Data Literature Source | [1]. Gu W,et al. Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol Pharm Bull. 2013;36(1):102-7 |
Unit | Bottle |
Specification | 10mg 10mM*1mL in DMSO 20mg |